{
    "text_blocks": {
        "data": {
            "block_count": 1,
            "table_index": 0
        },
        "model": null,
        "timestamp": "2025-01-21_09-41-26"
    },
    "table_comments": {
        "data": "CONSOLIDATED BALANCE SHEETS\t(Unaudited)\tSeptember 30,\tDecember 31,\t(In millions except share and per share amounts)\t2023\t2022\t",
        "timestamp": "2025-03-11_12-43-50"
    },
    "units": {
        "data": {
            "sum_units": 1000000,
            "sum_divider": 1.0
        },
        "model": {
            "gpt-4o-mini-2024-07-18": {
                "votes": {
                    "0": "1000000",
                    "1": "1000000"
                },
                "decision": "1000000"
            },
            "gpt-4o-2024-08-06": {
                "votes": null,
                "decision": null
            }
        },
        "timestamp": "2025-03-11_12-43-53"
    },
    "post_table_text": {
        "data": "\tThe accompanying notes are an integral part of these condensed consolidated financial statements.\t3",
        "model": {
            "gpt-4o-mini-2024-07-18": {
                "trials": {
                    "0": "'\tThe accompanying notes are an integral part of these condensed consolidated financial statements.\t3'"
                },
                "decision": "'\tThe accompanying notes are an integral part of these condensed consolidated financial statements.\t3'"
            },
            "gpt-4o-2024-08-06": {
                "trials": {},
                "decision": null
            }
        },
        "timestamp": "2025-03-11_12-43-55"
    },
    "table_body": {
        "data": "Assets\tCurrent assets:\tCash and cash equivalents\t$\t6,151\t$\t8,524\tAccounts receivable, less allowances of $\t184\tand $\t189\t8,370\t8,115\tInventories\t5,404\t5,634\tContract assets, net\t1,465\t1,312\tOther current assets\t1,702\t1,644\tTotal current assets\t23,092\t25,229\tProperty, plant and equipment, net\t9,167\t9,280\tAcquisition-related intangible assets, net\t17,091\t17,442\tOther assets\t4,124\t4,007\tGoodwill\t43,583\t41,196\tTotal assets\t$\t97,057\t$\t97,154\tLiabilities, redeemable noncontrolling interest and equity\tCurrent liabilities:\tShort-term obligations and current maturities of long-term obligations\t$\t4,795\t$\t5,579\tAccounts payable\t2,508\t3,381\tAccrued payroll and employee benefits\t1,460\t2,095\tContract liabilities\t2,547\t2,601\tOther accrued expenses\t2,848\t3,354\tTotal current liabilities\t14,158\t17,010\tDeferred income taxes\t2,620\t2,849\tOther long-term liabilities\t4,326\t4,238\tLong-term obligations\t30,489\t28,909\tRedeemable noncontrolling interest\t118\t116\tEquity:\tThermo Fisher Scientific Inc. shareholders  equity:\tPreferred stock, $\t100\tpar value,\t50,000\tshares authorized;\tnone\tissued\t \t \tCommon stock, $\t1\tpar value,\t1,200,000,000\tshares authorized;\t441,889,500\tand\t440,668,112\tshares issued\t442\t441\tCapital in excess of par value\t17,165\t16,743\tRetained earnings\t45,869\t41,910\tTreasury stock at cost,\t55,517,179\tand\t50,157,275\tshares\t(\t15,121\t)\t(\t12,017\t)\tAccumulated other comprehensive income/(loss)\t(\t3,027\t)\t(\t3,099\t)\tTotal Thermo Fisher Scientific Inc. shareholders  equity\t45,328\t43,978\tNoncontrolling interests\t18\t54\tTotal equity\t45,346\t44,032\tTotal liabilities, redeemable noncontrolling interest and equity\t$\t97,057\t$\t97,154",
        "timestamp": "2025-03-11_12-43-55"
    },
    "table_json_created": {
        "data": true,
        "model": {
            "gpt-4o-mini-2024-07-18": {
                "trials": {
                    "0": "{\"Assets\": {\"Current assets\": {\"Cash and cash equivalents\": [6151, 8524], \"Accounts receivable, less allowances of $ 184 and $ 189\": [8370, 8115], \"Inventories\": [5404, 5634], \"Contract assets, net\": [1465, 1312], \"Other current assets\": [1702, 1644], \"Total current assets\": [23092, 25229]}, \"Property, plant and equipment, net\": [9167, 9280], \"Acquisition-related intangible assets, net\": [17091, 17442], \"Other assets\": [4124, 4007], \"Goodwill\": [43583, 41196], \"Total assets\": [97057, 97154]}, \"Liabilities, redeemable noncontrolling interest and equity\": {\"Current liabilities\": {\"Short-term obligations and current maturities of long-term obligations\": [4795, 5579], \"Accounts payable\": [2508, 3381], \"Accrued payroll and employee benefits\": [1460, 2095], \"Contract liabilities\": [2547, 2601], \"Other accrued expenses\": [2848, 3354], \"Total current liabilities\": [14158, 17010]}, \"Deferred income taxes\": [2620, 2849], \"Other long-term liabilities\": [4326, 4238], \"Long-term obligations\": [30489, 28909], \"Redeemable noncontrolling interest\": [118, 116], \"Equity\": {\"Thermo Fisher Scientific Inc. shareholders equity\": {\"Preferred stock, $ 100 par value, 50,000 shares authorized; none issued\": [0, 0], \"Common stock, $ 1 par value, 1,200,000,000 shares authorized; 441,889,500 and 440,668,112 shares issued\": [442, 441], \"Capital in excess of par value\": [17165, 16743], \"Retained earnings\": [45869, 41910], \"Treasury stock at cost, 55,517,179 and 50,157,275 shares\": [-15121, -12017], \"Accumulated other comprehensive income/(loss)\": [-3027, -3099], \"Total Thermo Fisher Scientific Inc. shareholders equity\": [45328, 43978]}, \"Noncontrolling interests\": [18, 54], \"Total equity\": [45346, 44032]}, \"Total liabilities, redeemable noncontrolling interest and equity\": [97057, 97154]}}"
                },
                "decision": "{\"Assets\": {\"Current assets\": {\"Cash and cash equivalents\": [6151, 8524], \"Accounts receivable, less allowances of $ 184 and $ 189\": [8370, 8115], \"Inventories\": [5404, 5634], \"Contract assets, net\": [1465, 1312], \"Other current assets\": [1702, 1644], \"Total current assets\": [23092, 25229]}, \"Property, plant and equipment, net\": [9167, 9280], \"Acquisition-related intangible assets, net\": [17091, 17442], \"Other assets\": [4124, 4007], \"Goodwill\": [43583, 41196], \"Total assets\": [97057, 97154]}, \"Liabilities, redeemable noncontrolling interest and equity\": {\"Current liabilities\": {\"Short-term obligations and current maturities of long-term obligations\": [4795, 5579], \"Accounts payable\": [2508, 3381], \"Accrued payroll and employee benefits\": [1460, 2095], \"Contract liabilities\": [2547, 2601], \"Other accrued expenses\": [2848, 3354], \"Total current liabilities\": [14158, 17010]}, \"Deferred income taxes\": [2620, 2849], \"Other long-term liabilities\": [4326, 4238], \"Long-term obligations\": [30489, 28909], \"Redeemable noncontrolling interest\": [118, 116], \"Equity\": {\"Thermo Fisher Scientific Inc. shareholders equity\": {\"Preferred stock, $ 100 par value, 50,000 shares authorized; none issued\": [0, 0], \"Common stock, $ 1 par value, 1,200,000,000 shares authorized; 441,889,500 and 440,668,112 shares issued\": [442, 441], \"Capital in excess of par value\": [17165, 16743], \"Retained earnings\": [45869, 41910], \"Treasury stock at cost, 55,517,179 and 50,157,275 shares\": [-15121, -12017], \"Accumulated other comprehensive income/(loss)\": [-3027, -3099], \"Total Thermo Fisher Scientific Inc. shareholders equity\": [45328, 43978]}, \"Noncontrolling interests\": [18, 54], \"Total equity\": [45346, 44032]}, \"Total liabilities, redeemable noncontrolling interest and equity\": [97057, 97154]}}"
            },
            "gpt-4o-2024-08-06": {
                "trials": {},
                "decision": null
            }
        },
        "timestamp": "2025-03-12_11-46-13"
    },
    "problems": {
        "data": [],
        "timestamp": "2025-03-12_11-46-13"
    }
}